Targeted Antioxidant Deactivator
2013
“Unless we can find ways of reducing antioxidant levels, late-stage cancer 10 years from now will be as incurable as it is today.”
James D. Watson,
Nobel Laureate,
Director of Human Genome project
2024
ARJUNA Therapeutics has developed Ag5: The first cancer-mitochondrial-specific antioxidant deactivator. A unique small molecule to prolong the lifespan of patients with clinical stage cancer and redefine standard of care across solid tumours.
Overview
Therapeutic Molecular Clusters
Therapeutic Molecular Clusters takes a new approach to cancer treatments. Our lead drug acts as a catalyst and we are targeting a known Achilles heel for multiple cancer indications.
Novel Platform, Novel Medicine
Therapeutic Molecular Clusters (TMC's) are a new class of medicine that act as catalysts within the cell structure. We influence a reaction without being permanently altered or consumed by the process.
Removing The Fear From Cancer
Removing The Fear From Cancer
Arjuna biotech medical research and development. As any person with cancer knows, a diagnosis of cancer also affects every family member and a broader network of relationships. Our vision is to remove the fear of a cancer diagnosis for every patient and every family.